PUMA BIOTECHNOLOGY, INC.
Income Statement
| Line Item | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.6M | $51.2M | $62.9M | $56.4M | $53.9M | $99.1M | $71.1M | $62.6M |
| Cost of Revenue | — | — | — | — | $9.3M | $8.0M | $10.4M | $9.0M |
| Gross Profit | — | — | — | — | $44.6M | $91.1M | $60.7M | $53.6M |
| Gross Margin | — | — | — | — | 82.7% | 91.9% | 85.4% | 85.6% |
| Operating Expenses | ||||||||
| Research & Development | $24.7M | $25.5M | $30.2M | $30.0M | $36.9M | $35.7M | $38.3M | $36.4M |
| SG&A Expense | $29.3M | $30.9M | $31.2M | $31.4M | $33.5M | $45.5M | $40.9M | $28.5M |
| Operating Income | $7.1M | $-14.3M | $-8.7M | $-14.4M | $-25.8M | $9.8M | $-18.5M | $-11.3M |
| Operating Margin | 10.1% | -27.8% | -13.8% | -25.6% | -47.8% | 9.9% | -26.1% | -18.0% |
| Interest Expense | $3.8M | $3.1M | $3.1M | $3.1M | $4.4M | $4.4M | $3.8M | $3.5M |
| Pretax Income | $3.4M | $-16.9M | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $3.4M | $-16.9M | $-11.2M | $-16.9M | $-37.4M | $-10.1M | $-30.7M | $-14.2M |
| Net Margin | 4.8% | -33.1% | -17.8% | -30.0% | -69.4% | -10.2% | -43.2% | -22.7% |
| EPS (Basic) | $0.09 | $-0.43 | $-0.29 | $-0.44 | $-0.97 | $-0.26 | $-0.80 | $-0.37 |
| EPS (Diluted) | $0.08 | $-0.43 | $-0.29 | $-0.44 | $-0.97 | $-0.26 | $-0.80 | $-0.37 |
| Shares Outstanding (Basic) | 39.4M | 39.3M | 39.2M | 38.9M | 38.6M | 38.6M | 38.3M | 38.1M |
| Shares Outstanding (Diluted) | 40.0M | 39.3M | 39.2M | 38.9M | 38.6M | 38.6M | 38.3M | 38.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |